BLOCH KATHLEEN P.

SEC source: 0001104659-24-043793 · tm2411149-2_4seq1.xml · derivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,000

Underlying: Common Stock · 87,000 shares

Expires 2034-04-02

F6 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043793 · tm2411149-2_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 532,941

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes: (i) the following RSUs, which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into common stock, par value $0.001 per share (the "Common Stock"), upon vesting: 20,000 RSUs granted on September 18, 2023;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs, which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and

F5 · balance_after: (continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-24-042774 · tm2410664-2_4seq1.xml · derivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,038

Underlying: Common Stock · 49,038 shares

Expires 2034-03-29

F1 · price: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-126427 · tm2332958-2_4seq1.xml · derivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,157

Underlying: Common Stock · 13,157 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant

SEC source: 0001104659-23-126427 · tm2332958-2_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 467,941

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant

F2 · balance_after: Includes: (i) the following restricted stock units ("RSUs") (which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into Common Stock upon vesting: 20,000 RSUs granted on September 18, 2023;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and

F5 · balance_after: (continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-102316 · tm2326524-1_4seq1.xml · derivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-09-18

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options shall vest as follows: (i) 10,000 shares underlying these stock options shall vest on the date of grant, (ii) 10,000 shares underlying these stock options shall vest on the first anniversary of the date of grant, and (iii) 10,000 underlying these stock options shall vest on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-102316 · tm2326524-1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 442,347

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as follows: (i) 25,000 RSUs shall vest on the date of grant, (ii) 10,000 RSUs shall vest on the first anniversary of the date of grant, and (iii) 10,000 RSUs shall vest on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") of CytoSorbents Corporation (the "Company") upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock of the Company upon vesting: 18,500 RSUs granted on August 10, 2022; and

F4 · balance_after: (continued from footnote 3) (iii) 197,347 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-23-080106 · tm2321021-8_4seq1.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-07-07

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest fully on the first anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-065680 · tm2317159-1_4seq1.xml · nonDerivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 47,000

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-065680 · tm2317159-1_4seq1.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 45,900

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-065680 · tm2317159-1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 44,800

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-059389 · tm2315569-1_4seq1.xml · nonDerivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 43,700

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-059389 · tm2315569-1_4seq1.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 40,700

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-23-059389 · tm2315569-1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Interim CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 38,700

F1 · ownership.nature: These shares are held by the Reporting Person's husband in a 401(k) account. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-22-090247 · tm2223355-3_4seq1.xml · derivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,000

Underlying: Common Stock · 215,000 shares

Expires 2032-08-10

F7 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest only upon the achievement of certain milestones before December 31, 2025. Specifically, (i) 45,000 options will vest if the Company obtains U.S. Food and Drug Administration approval for its product DrugSorb, (ii) 45,000 options will vest if the Company achieves $80 million or more in annual ex-U.S. sales, (iii) 50,000 options will vest if the Company achieves $20 million or more in annual U.S. sales, and (iv) 75,000 options will vest if the Company achieves U.S. GAAP breakeven.

SEC source: 0001104659-22-090247 · tm2223355-3_4seq1.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2032-08-10

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090247 · tm2223355-3_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 405,161

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into Common Stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock of the Company upon vesting: (a) 16,484 RSUs granted on April 12, 2021 and unvested as of the date hereof and (b) 55,500 RSUs granted on August 10, 2022 reported on this Form 4 and unvested as of the date hereof; and

F4 · balance_after: (continued from footnote 3) (iii) 151,677 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-22-068656 · tm2217836-1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 33,700

F1 · ownership.nature: Includes (i) 10,000 shares held by the Reporting Person's husband in a 401(k) account, (ii) 15,000 shares held by the Reporting Person's husband in an IRA account and (iii) 8,700 shares held by the Reporting Person's husband in a ROTH IRA account and reported on this Form 4. The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-21-144035 · tm2134006-1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 25,000

F1 · ownership.nature: Includes (i) 10,000 shares held by the Reporting Person's husband in a 401(k) account and (ii) 15,000 shares held by the Reporting Person's husband in an IRA account (including the 4,000 shares reported on this Form 4). The Reporting Person may be deemed the beneficial owner of such shares.

SEC source: 0001104659-21-050387 · tm2113016d2_4.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2031-04-12

F5 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-21-050387 · tm2113016d2_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 375,372

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

F3 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock of the Company upon vesting: (a) 49,450 RSUs granted on April 12, 2021 and unvested as of the date hereof, (b) 14,334 RSUs granted on February 28, 2020 and unvested as of the date hereof and (c) 14,334 RSUs granted on July 22, 2019 and unvested as of the date hereof; and (iii) 115,754 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-21-000337 · tm211481d1_4seq1.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,793

Underlying: Common Stock · 7,857 shares

Expires 2027-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: These stock options were originally granted on February 24, 2017 and became exercisable upon achievement of certain performance goals as determined in the discretion of the Compensation Committee of the Board of Directors of the Company.

SEC source: 0001104659-21-000337 · tm211481d1_4seq1.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,013

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Company's 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018;

F2 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock, par value $0.001 per share (the "Common Stock") of the Company upon vesting: (a) 28,667 RSUs granted on February 28, 2020 and unvested as of the date hereof, (b) 14,334 RSUs granted on July 22, 2019 and unvested as of the date hereof and (c) 1,358 RSUs granted on March 4, 2019 and unvested as of the date hereof; and

F3 · balance_after: (iii) 107,154 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-20-090308 · tm2026522d1_4.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,650

Underlying: Common Stock · 10,000 shares

Expires 2027-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: These stock options were originally granted on February 24, 2017 and became exercisable upon achievement of certain performance goals as determined in the discretion of the Compensation Committee of the Board of Directors of the Company.

SEC source: 0001104659-20-090308 · tm2026522d1_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,156

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Company's 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018; (continue with footnote 2)

F2 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock, par value $0.001 per share (the "Common Stock") of the Company upon vesting: (a) 28,667 RSUs granted on February 28, 2020 and unvested as of the date hereof, (b) 14,334 RSUs granted on July 22, 2019 and unvested as of the date hereof and (c) 1,358 RSUs granted on March 4, 2019 and unvested as of the date hereof; and (iii) 99,297 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-20-028654 · tm2011575d3_form4.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-02-28

F4 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-20-028654 · tm2011575d3_form4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,828

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Company's 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018; (ii) the following RSUs subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting: (a) 43,000 RSUs granted on February 28, 2020 and reported on this Form 4, (b) 28,667 RSUs granted on July 22, 2020 and unvested as of the date hereof and (c) 2,714 RSUs granted on March 4, 2019 and unvested as of the date hereof; and (iii) 72,947 shares of common stock owned by the reporting person.

SEC source: 0001104659-19-071352 · tm1924904d1_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 291,895

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon a "Change In Control" of the issuer, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016, and (d) 110,000 RSUs granted on April 8, 2015; (ii) the following unvested RSUs that are subject to vesting in three equal annual installments with the first installment vesting on the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and that will be settled into common stock upon vesting: (a) 28,667 RSUs granted on July 22, 2019, (b) 11,567 RSUs granted on February 28, 2018, and (c) 2,714 RSUs granted on March 4, 2019; and (iii) 67,447 shares of common stock owned by the reporting person, inclusive of the 3,000 shares of common stock reported on this Form 4.

SEC source: 0001104659-19-067732 · tm1923981d1_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 21,000

F1 · ownership.nature: Includes (i) 10,000 shares held by the reporting person's husband in a 401(k) account (including the 1,000 shares reported on this Form 4) and (ii) 11,000 shares held by the reporting person's husband in an IRA account. The reporting person may be deemed the beneficial owner of all such shares.

SEC source: 0001144204-19-040422 · tv527863_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 20,000

F1 · ownership.nature: Includes (i) 9,000 shares held by the reporting person's husband in a 401(k) account and (ii) 11,000 shares held by the reporting person's husband in an IRA account, including the 6,500 shares reported on this Form 4. The reporting person may be deemed the beneficial owner of such shares.

SEC source: 0001144204-19-039650 · tv527557_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 13,500

F1 · ownership.nature: Includes (i) 9,000 shares held by the reporting person's husband in a 401(k) account and (ii) 4,500 shares held by the reporting person's husband in an IRA account, including the 1,500 shares reported on this Form 4. The reporting person may be deemed the beneficial owner of such shares.

SEC source: 0001144204-19-035843 · tv525810_4.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2029-07-22

F4 · derivative.exercise_date: The stock option was granted pursuant to the Plan. The shares underlying the stock option vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001144204-19-035843 · tv525810_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,725

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018; (ii) the following RSUs subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting: (a) 43,000 RSUs granted on July 22, 2019 and reported on this Form 4, (b) 11,567 RSUs granted on February 28, 2018 and unvested as of the date hereof and (c) 2,714 RSUs granted on March 4, 2019 and unvested as of the date hereof; and (iii) 56,944 shares of common stock owned by the reporting person.

SEC source: 0001144204-19-030603 · tv523397_4.xml · derivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,650

Underlying: Common Stock · 10,000 shares

Expires 2027-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: On February 24, 2017, the reporting person was granted an option to purchase 89,000 shares of common stock pursuant to the Plan, which was to vest upon achievement of certain performance goals as determined in the discretion of the Compensation Committee of the Board of Directors of the Company. This grant was reported on a Form 4 filed on February 28, 2017. On February 28, 2018, the Compensation Committee of the Board of Directors of the Company determined that 85% of such performance criteria was achieved during 2017, resulting in vesting of 75,650 shares underlying this option.

SEC source: 0001144204-19-030603 · tv523397_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,725

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Company's 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,567 RSUs granted on February 28, 2018 and unvested as of the date hereof and (b) 2,714 RSUs granted on March 4, 2019 and unvested as of the date hereof and (iii) 56,944 shares of common stock owned by the reporting person, including the shares reported herein.

SEC source: 0001144204-19-025962 · tv521603_form4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.4466 to $6.4984, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

F2 · ownership.nature: These shares were acquired by the reporting person's husband and, as such, the reporting person may be deemed the beneficial owner of such shares.

SEC source: 0001144204-19-012635 · tv515702_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,725

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation, as defined in the 2014 Long-Term Incentive Plan: (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,567 RSUs granted on February 28, 2018 and unvested as of the date hereof and (b) 4,070 RSUs granted on March 4, 2019 and reported on this Form 4 and (iii) 45,588 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-047336 · tv502084_4.xml · derivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2023-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017 (the "Trading Plan").

F4 · derivative.exercise_date: These options became exercisable upon the achievement of certain milestones connected to the Company's operations, as determined by the Company's Board of Directors.

SEC source: 0001144204-18-047336 · tv502084_4.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,004

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017 (the "Trading Plan").

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, and (b) 23,134 RSUs granted on February 28, 2018 and unvested as of the date hereof and (iii) 34,432 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-047336 · tv502084_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,004

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017 (the "Trading Plan").

SEC source: 0001144204-18-042396 · tv500351_4.xml · derivative · entry 6

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2023-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017 (the "Trading Plan").

F4 · derivative.exercise_date: These options became exercisable upon the achievement of certain milestones connected to the Company's operations, as determined by the Company's Board of Directors.

SEC source: 0001144204-18-042396 · tv500351_4.xml · nonDerivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,004

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017 (the "Trading Plan").

F5 · price: The reporting person received an additional $0.599 per share pursuant to the terms of the Trading Plan.

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, and (b) 23,134 RSUs granted on February 28, 2018 and unvested as of the date hereof and (iii) 34,432 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-042396 · tv500351_4.xml · nonDerivative · entry 3

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,604

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017 (the "Trading Plan").

SEC source: 0001144204-18-042396 · tv500351_4.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 259,804

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017 (the "Trading Plan").

SEC source: 0001144204-18-042396 · tv500351_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,004

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017 (the "Trading Plan").

SEC source: 0001144204-18-029352 · tv494430_4.xml · derivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,400 shares

Expires 2026-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-029352 · tv494430_4.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,304

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested, (b) 7,000 of the RSUs granted on June 7, 2016 and unvested, and (c) 23,134 RSUs granted on February 28, 2018 and unvested and (iii) 30,732 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-029352 · tv494430_4.xml · nonDerivative · entry 1

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,704

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-029351 · tv494429_4.xml · derivative · entry 4

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,400

Underlying: Common Stock · 12,400 shares

Expires 2026-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

SEC source: 0001144204-18-029351 · tv494429_4.xml · nonDerivative · entry 2

BLOCH KATHLEEN P. · CIK 0001409212 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,304

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2017.

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the 2014 Long-Term Incentive Plan (the "Plan"): (a) 15,700 RSUs granted on February 24, 2017, (b) 47,000 RSUs granted on June 7, 2016, (c) 110,000 RSUs granted on April 8, 2015, and (d) 8,800 RSUs granted on March 15, 2018, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 10,938 of the RSUs granted to the reporting person on February 24, 2017 and unvested, (b) 7,000 of the RSUs granted on June 7, 2016 and unvested, and (c) 23,134 RSUs granted on February 28, 2018 and unvested and (iii) 30,732 shares of common stock owned by the reporting person.